AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN FRANCISCO -- Almost half of patients on flexible-dosing schedules of extended-release oxybutynin for urge incontinence chose a dose of more than 10 mg/day, the level employed in two fixed-dose trials of the medication, Peter K. Sand, M.D., and Scott A. MacDiarmid, M.D., reported in a poster presentation at the annual meeting of the American College of Obstetricians and Gynecologists.
In a combined analysis of 368 patients from three clinical trials employing flexible dosing schedules of 5-30 mg/day, 47% of participants chose a final dose of 15, 20, 25, or 30 mg/day.
At all selected final doses of oxybutynin, 77%-83% of the patients reportedly achieved a reduction of at least 70% in the number of urge in continence episodes, according to Dr. Sand of ...